The product is supplied under the model designation mPEG36-NH₂ (pharma grade) as a methoxy-terminated linear ethylene glycol 36-mer carrying a single primary amine terminus. The free-base composition is CH₃O-(CH₂CH₂O)36-CH₂CH₂NH₂, and the calculated monoisotopic mass is approximately 1661 Da. The material is isolated as a discrete single-chain oligomer rather than as a molecular-weight distribution; this structural feature separates it from conventional polydisperse mPEG-amine products with the same nominal mass range. The product is an off-white to white waxy solid at controlled room temperature, with a typical melting range of 42–48 °C and a 10% w/w aqueous solution pH of 9.0–10.5 at 25 °C. Water solubility exceeds 500 mg/mL at 20 °C; solubility is also observed in ethanol, dichloromethane, and acetonitrile, while cold hexane provides only limited dissolution.

In pharmaceutical processing, the primary amine is used for amide coupling with carboxylated active substances, for surface modification of pre-formed granules, and as a reactive hydrophilic segment in injectable conjugates. Because the amine content can be expressed on an exact molar basis, the required stoichiometric charge for an active pharmaceutical ingredient of known carboxyl content is calculated directly rather than by using an average molecular mass. The product is not a finished dosage form; it is an active-substance modifier or intermediate, and its acceptance into a formulation must be supported by the finished-product control strategy.

The pharma grade is differentiated from reagent-grade mPEG-amine by tighter control of residual solvents, bacterial endotoxins, bioburden, water content, peroxide value, and elemental impurities. The selection of oral or injectable grade depends on the route of administration; injectable grade is required for parenteral manufacture, while oral solid-dose processes may use oral grade only when a documented risk assessment demonstrates that the lower-purity grade does not affect the finished product specification.

What Limits the Use of Polydisperse PEG Amine Grades in Conjugation Stoichiometry?

Conventional mPEG-amine products are specified by average molecular mass, but the actual material contains a distribution of ethylene oxide oligomers. In a coupling reaction with an acid chloride, two lots of a polydisperse grade with the same label claim can deliver different molar amine concentrations depending on the hidden low-mass and high-mass tails. This variation is amplified when the PEG segment governs solubility, clearance, or hydrodynamic radius. The discrete 36-mer avoids this problem because only one oligomer, with a defined [M+H]⁺ value, is present. Mass-directed purification and LC-MS release testing can therefore assign each detected species to a single molecular ion rather than to a cluster of homologues separated by 44 Da.

For oral solid dosage forms, the difference is less critical when the polymer is used only as a binder or coating modifier. For injectable conjugates and for active substances with narrow therapeutic windows, the discrete structure avoids product-definition ambiguity and reduces the number of release-test variables that must be justified in regulatory submissions.

Specifications, Residual Solvents, and Elemental Impurity Limits

The pharma grade certificate of analysis reports orthogonal lot-release results. Water content is controlled because the terminal amine and polyether chain are hygroscopic; water uptake accelerates oxidation and can alter the mass balance in a coupling reaction. Residual solvent levels follow ICH Q3C principles, and elemental impurities are assessed against ICH Q3D limits for the intended route.

These limits are release controls for the product as supplied. They do not replace the finished dosage form specification; a formulation-specific risk assessment must address the potential introduction of ethylene glycol-related impurities into the final product. Published data for this specific configuration is limited in public regulatory filings, so each site should establish internal acceptance ranges using at least three consecutive production lots before locking the specification.

When Methoxy PEG36 Amine Is Compounded into Tablet and Capsule Granules

In low-dose oral tablet manufacture, the product has been evaluated as a reactive carrier for poorly water-soluble actives when the amine is first coupled to the active substance and the resulting conjugate is then dispersed in the granulating fluid. Published data for this specific configuration is limited; therefore, process development should not rely on prior polydisperse PEG data without confirmation of crystalline form, compatibility, and dissolution behaviour.

For high-shear wet granulation, the product is dissolved in purified water to a target concentration of 5–15% w/w. The solution should be added through a peristaltic pump at a rate matched to the mass of granulate; typical tip speeds in a laboratory high-shear mixer are 1–3 m/s. If the formulation contains lactose, the aqueous granulation temperature is maintained below 35 °C because the primary amine can form Schiff-base adducts with open-chain reducing sugars. Anhydrous lactose or non-reducing fillers such as mannitol and dibasic calcium phosphate are preferred when the amine concentration exceeds 2% w/w of the dry granulate.

After drying, residual moisture is controlled at 1.5–2.5% w/w before compression. On a rotary tablet press, compression forces of 12–18 kN have been used to produce tablets with breaking force 60–90 N; hardness testing follows USP <1217>. Tablet disintegration is evaluated by USP <701>, with an immediate-release target of <15 min in purified water at 37 °C. For capsule-grade granules, the same granulate can be filled into hard gelatin capsules; the amine-bearing granulate should not be stored above 25 °C without desiccant because moisture and primary amine groups may accelerate crosslinking in the shell.

Granule flow and tablet ejection force depend on moisture and residual solvent content. Before full-scale compression, an instrumented tablet press equipped with compaction force and ejection force transducers should be used to define the upper ejection force limit. If ejection force exceeds the limit, magnesium stearate is added at 0.25–0.5% w/w, but mixing time is limited to 3 min because prolonged shear may distribute the lubricant over the amine-bearing granules and reduce tablet hardness. These limits are established with USP-grade excipients and should be re-qualified after any change in granule particle size distribution.

Injectable-Grade mPEG36-NH₂ Meets Parenteral Endotoxin and Particulate Control Requirements

Injectable use requires the pharma grade with documented endotoxin, bioburden, and particulate controls; oral grade material is not interchangeable. For parenteral compounding, a 10% w/w aqueous solution of the product is prepared in Water for Injection and passed through a 0.22 µm PVDF or polyethersulfone membrane. Mixed cellulose ester membranes have a higher leachable risk in PEG-containing solutions and are avoided unless extractables data support their use.

Solution viscosity at 10% w/w remains low enough for standard peristaltic membrane dosing; however, the amine can raise the local pH to 9, which may destabilise acid-labile active substances. The solution is therefore back-titrated with sterile acid to pH 6.0–6.8 before addition. Nitrogen overlay is used during dissolution and filling to limit oxidative degradation of the terminal amine and the polyether chain; prolonged exposure to headspace oxygen generates peroxides that can be measured by a pharmacopoeial peroxide-value method.

For terminal sterilisation, the product can be autoclaved in sealed glass vials at 121 °C for 15 min, but a small colour change may occur if residual oxygen is present. Filter-sterilisation is an alternative when terminal heat is not tolerable. After filtration, the finished solution is tested according to Ph. Eur. 2.9.19 for sub-visible particulates and Ph. Eur. 2.6.14 for bacterial endotoxins. Because the product has a discrete molecular mass, the osmolality contribution can be calculated from the molar mass of 1661 Da; osmolality is measured by freezing-point depression following Ph. Eur. 2.2.35.

For injectable formulations that undergo terminal heat treatment, a compatibility study with the primary container is performed because low-molecular-weight PEGs can extract leachables from certain closures. The product is preferably filled in glass vials with fluoropolymer-coated chlorobutyl stoppers. The stability of the finished injectable solution is validated at 2–8 °C and at controlled room temperature; freeze-thaw studies are required if the formulation is stored frozen because the amine-bearing conjugate may distribute differently between ice and freeze-concentrated solute phases.

Qualifying Identity, Purity, and Peroxide Levels for Lot Release

Because the product lacks a strong UV chromophore, purity release is performed with charged aerosol detection or evaporative light scattering detection rather than UV absorbance. Under UHPLC-CAD, the single oligomer peak is reported at the retention time of the reference standard, and a limit of ≥98.0 area% is applied after correcting for system peaks. Fourier transform infrared spectroscopy, mass spectrometry, and nuclear magnetic resonance are used for identity; the mass spectrum displays a protonated molecule at 1661 Da with no envelope of homologues separated by 44 Da.

The active amine value is expressed in milliequivalents per gram. For a single monofunctional 36-mer of 1661 Da, the theoretical value is 0.602 meq/g; the acceptance range is typically 0.58–0.62 meq/g. Titrimetric amine determination is performed in alcoholic solvent with potentiometric endpoint detection; colourimetric trinitrobenzenesulfonic acid can be used as an orthogonal test. Peroxide value is controlled at ≤2.0 meq/kg; this limit is critical for injectable formulations because peroxide impurities can oxidise unsaturated active substances and contribute to particle formation.

Water content is determined by Karl Fischer titration, with a release limit of ≤1.0% w/w. The product is hygroscopic above 60% relative humidity; therefore, sampling is performed under nitrogen or in a dry glovebox after the container has been equilibrated to ambient temperature. Unused material is returned to an airtight container under nitrogen and stored at −20 °C for long-term inventory, although controlled room temperature is acceptable for short-term use up to the date stated on the certificate of analysis.

The discrete nature of the material allows mass spectrometric lot confirmation without the broad oligomer envelope that complicates identity testing of polydisperse PEG grades. For release in injectable applications, the molecular ion at 1661 Da is confirmed against a reference standard, and the absence of the 44 Da homologue series is recorded as part of the lot identity file.

In lyophilised injectable processing, the product is added as a carrier or conjugate segment after the active substance has been pH-adjusted to 6.0–6.8. The freeze-thaw behaviour of a 10% aqueous solution has been evaluated in a pilot lyophiliser with a shelf cooling rate of 1 °C/min; macroscopic cracking of the frozen plug is not observed when the fill depth is held below 2.0 cm, although published data for this specific configuration is limited. The annealing step is performed at −10 °C for 2 h to allow crystallisation of free water before primary drying.

Primary drying is conducted at −30 °C shelf temperature and 50 mTorr chamber pressure; the product is then ramped to 25 °C over 5 h for secondary drying. The lyophilised cake is characterised by near-white appearance and moisture below 1.0% w/w by Karl Fischer titration. If the formulation contains oxidisable active substances, the cake is sealed under reduced pressure or nitrogen and protected from light. This grade is not recommended for aqueous solution formulations that undergo terminal steam sterilisation in a plastic primary container because PEG may extract leachables from polyvinyl chloride; glass or cyclic-olefin polymer containers are preferred.